Case reports demonstrate lebrikizumab improved symptoms in patients with severe atopic dermatitis, suggesting new options.
The treatment landscape for moderate‐to‐severe atopic dermatitis (AD) has evolved significantly with the introduction of novel targeted therapies addressing specific pathogenic mechanisms of the disease. Despite this therapeutic revolution, a proportion of patients experience intolerance and/or inadequate response to multiple lines of treatment, highlighting the need for new therapeutic options. Lebrikizumab, a monoclonal IgG4 humanized antibody that selectively targets interleukin (IL)−13, has been recently approved for AD treatment. We present two case reports of multimorbid, difficult‐to‐treat patients who achieved successful disease control with lebrikizumab treatment.
No takes yet. Share an insight, caveat, or question.
Ippoliti et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: